Health

Denver could soon become the first US city to decriminalize ‘magic’ mushrooms

Magic mushrooms
Psilocybin is currently considered a schedule 1 drug by the Drug Enforcement Administration. AP Photo/Chiaki Tsukumo
Read in app

On May 7, Denver, Colorado, residents will decide whether the city will be the first in the United States to decriminalize psychedelic mushrooms. Residents will vote on whether to eliminate the possibility of felony charges for people found possessing the substance.

Kevin Matthews, the campaign director of Decriminalize Denver, the initiative spearheading local decriminalization efforts, told NBC 9 in January that his team collected 8,000 signatures to advance the measure to the May ballot. In Denver, 4,279 signatures are needed to move a measure along, and the city's elections office has 25 days to verify the signatures.

Psilocybin is currently a Schedule 1 drug in the US, meaning it is considered to have has no medical use and a high potential for abuse. As a result of this, psilocybin is largely unavailable in the country and is illegal to possess. Decriminalization of the substance in Denver means psilocybin would remain illegal, but people 21 and over who possess it would have a lower likelihood of being arrested and put in jail.

Psilocybin decriminalization could protect families and encourage research

If passed, the policy would make anyone 21 or older who possesses psilocybin the "lowest law enforcement priority," NBC 9 reported.

According to Matthews, the measure could keep more families together. "The main reason we are doing this is to keep people out of prison," Matthews told INSIDER. "[We] don't want to have people lose their children, and we believe it's the best and necessary first step to reintegrate psilocybin back into society and encourage more research as well."

Psilocybin research has been limited in the US, but some preliminary studies have found that the psychedelic drug has the potential to treat anxiety and depression.

In one 2016 study, researchers at Johns Hopkins University gave 29 cancer patients magic mushrooms in combination with psychotherapy sessions to help with depression and anxiety they reported as a result of their diagnoses. The patients who recieved psilocybin reported immediate reductions in anxiety and depression.

Matthews told INSIDER that a vote for psilocybin decriminalization could spur more research on the drug's potential medical uses. Through campaigning, he has spoken with many proponents of the substance who said psilocybin has helped them with depression, cluster headaches, and anxiety. Matthews also told NBC 9 that psilocybin has helped him with his own depression.

Read more: A team of Johns Hopkins researchers is calling for magic mushrooms to be made legally available as medicine

In a phone poll of 172 Denver residents that his team conducted, 45% said they were in favor of decriminalization.

"We need people to come out of the psychedelic closet and share their experiences," Matthews said. "There is a deep cultural misunderstanding of psilocybin and what it does."

While growing psilocybin at home will remain illegal in Denver even if decriminalization passes, residents cultivating small amounts won't have to worry quite as much about being sent off to jail, according to Matthews.

He said that his team wants to create a "healthy relationship" with the city, so the decriminalization plan includes creating a panel of attorneys, health professionals, police, and city council members who can evaluate whether Decriminalize Denver's efforts help keep families together and free up government funds that are typically used to prosecute people in possession of psilocybin.

Peter Kotecki contributed to a previous version of this story.

Read more:

Read next

Headshot of Julia Naftulin
Julia Naftulin
Julia Naftulin is an editor on Business Insider's Special Projects team, where she leads editorial initiatives spanning the business, tech, and lifestyle spaces.She has launched and managed series covering how companies adopt and implement AIthe business of food, the 2026 World Cup, and innovation in supply chain management, as well as projects like the AI Power List.Previously, Julia served a five-year tenure as health reporter at Business Insider, covering general wellness and the intersection of relationships, psychology, and culture.Julia reported on the life of a Wall Street accountant-turned-professional-girlfriend, took readers inside Goop's first cruise, explored the dating industry, and delved into the latest plastic surgery trends. She was also Business Insider's resident relationship advice columnist, penning the now-defunct column Doing It Right.She has held editor roles at Health.com and Dotdash Meredith. Her work has been published in Health magazine and on Time, Apartment Therapy, The Knot, and Bicycling.com.Julia graduated from Syracuse University with a Bachelor of Science in Magazine Journalism. Julia lives in Philadelphia with her dachshund, Gretchen.